BCPharmaCare *Newsletter*

January 18, 2006
06-001
Page 1 of 1

Published by PharmaCare to provide information for British Columbia's community pharmacists.
Please circulate among dispensing staff.

Corrections to Benefit Information

Following are corrections to the benefit information published in PharmaCare Newsletter 05-007 of December 21, 2005. We regret any inconvenience the inaccurate information may have caused.

Benefits section

DIN 2256193 CESAMET® (nabilone) 0.5 mg capsules are manufactured by **Valeant Canada Limited** (not Eli Lilly Canada).

New LCA Categories section

DIN 2257963 CLARUS® (isotretinoin) 40 mg capsule: Manufacturer code should read **PHE** (not PRM).

Non-Benefits section

DIN 2269589 - Should read Rhoxal-**Glimepiride 1 mg** tablet (not Rhoxal-Mirtazapine).

DIN 2269597 - Should read Rhoxal-**Glimepiride 2 mg** tablet (not Rhoxal-Mirtazapine).

DIN 2269619 - Should read Rhoxal-**Glimepiride 4 mg** tablet (not Rhoxal-Mirtazapine 3 mg tablet).

LCA/RDP Booklet Corrections

The LCA category information for Azithromycin 250 mg tablets, effective **January 23, 2006**, should have read as follows:

- LCA benefit status for Co-Azithromycin (DIN 2255340) and Novo-Azithromycin (DIN 2267845) should have read full instead of partial.
- LCA category price should have read 3.5842 instead of 3.2970

CATEGORY				LCA PRICE	NEW STATUS
AZITHROMYCIN 250 mg tablet	2255340	OBT	CO-AZITHROMYCIN 250 mg tablet		F
	2267845	NOP	NOVO-AZITHROMYCIN 250 mg tablet		F
	2265826	RXP	SANDOZ-AZITHROMYCIN 250 mg tablet		F
	2212021	PFI	ZITHROMAX 250 mg tablet	3.5842	P

The use of PharmaNet is not intended as a substitute for professional judgment. Information on PharmaNet is not exhaustive and cannot be relied upon as complete. The absence of a warning about a drug or drug combination is not an indication that the drug or drug combination is safe, appropriate or effective in any given patient. Health care professionals should confirm information obtained from PharmaNet, and ensure no additional relevant information exists, before making patient care decisions.